On September 23, 2026, an FDA advisory panel did something no expert committee had done before: it formally reviewed a multi-cancer screening blood test and voted on whether its benefits outweigh its risks. The test is Galleri, made by GRAIL, and the panel’s answer was a qualified yes. That single sentence has already generated a wave of headlines, and it is easy to read too much into it. A panel recommendation is not an approval, an approval is not insurance coverage, and none of it changes what you should do with your own screening today.
This article sets aside the hype and focuses on the facts that came out of the meeting: how the panel actually voted, why the vote was closer than the headlines suggest, what happens between now and a final FDA decision, and what a blood test like this can and cannot tell you about cancer risk in the meantime.
How the panel actually voted
The Molecular and Clinical Genetics Panel of the FDA’s Medical Devices Advisory Committee did not cast one vote. It cast three, on three separate questions, and the results tell a more nuanced story than “the FDA panel approved a cancer test.”
- On whether the test is safe, the panel voted 10 to 0.
- On whether the test is effective, the panel voted 6 to 4, a narrow majority.
- On whether the benefits outweigh the risks, the panel voted 7 to 2, with one abstention.
One panel member reportedly described the benefit-risk vote as “a hopeful rather than an accurate one,” a comment that captures the mood of the meeting better than any single tally. The reviewers were not declaring the evidence settled. They were expressing conditional confidence, tied to the condition that Galleri is meant to add to existing screening, not to replace it.
Why a panel vote is not the same as approval
An FDA advisory committee provides independent scientific advice. Its votes are not binding, and the agency can take weeks or months to issue its own decision. An earlier article we published unpacks the full premarket approval process GRAIL’s application must still complete. What matters here is simpler: as of this vote, GRAIL’s premarket approval application is still under FDA review, and no multi-cancer detection test has yet been authorized by the FDA. That fact, confirmed by the National Cancer Institute, has not changed because of this meeting.
What actually changes today (and what doesn’t)
Nothing changes immediately for someone deciding whether to get tested this week. Galleri remains available in the United States as a laboratory-developed test, sold directly to consumers for roughly $700 to $900 out of pocket, according to figures reported around the panel meeting and by the National Cancer Institute. It is not covered by Medicare or by most private insurance, and that will not change unless and until the FDA issues a final decision and a separate coverage determination follows it.
The FDA is expected to make its own decision within a few months. It is free to follow the panel’s recommendation, narrow it, or reject it outright. Until then, the test’s regulatory status is exactly what it was on September 22: an unapproved, self-pay screening option.
What a positive decision would, and would not, mean for your own screening
Even a full approval would not turn Galleri into a replacement for the screenings that already have decades of evidence behind them. The panel’s own conditions made this explicit: the test is intended to complement, not substitute for, mammography, colonoscopy or stool-based testing, cervical cancer screening, and low-dose CT for people who qualify because of a smoking history.
A negative Galleri result does not mean you don’t have cancer. Sensitivity varies by cancer type and stage, and it is markedly lower for early-stage disease, which is precisely when detection matters most. A positive result is not a diagnosis either. According to the National Cancer Institute, more than half of positive multi-cancer detection results lead to follow-up workups that find no cancer at all, a burden that carries real cost, anxiety, and sometimes invasive procedures. Our earlier coverage examines the 2026 multi-cancer early detection trial results in more depth, including why the largest randomized trial of its kind has not yet met its main goal.
What already exists, compared with what Galleri would add
| Screening option | What it looks for | Evidence of a mortality benefit |
|---|---|---|
| Mammography | Breast cancer | Established in randomized trials |
| Colonoscopy or stool-based test | Colorectal cancer | Established, reduces incidence and deaths |
| Cervical cytology or HPV test | Cervical cancer | Established, prevents most cases |
| Low-dose CT (eligible smokers) | Lung cancer | Established in a high-risk population |
| Galleri (pending FDA decision) | A signal across more than 50 cancer types | Not yet demonstrated in a completed randomized trial |
Latest scientific advances
Two recent papers help explain why the panel’s caution matters, and why the conversation around multi-cancer blood tests is shifting from “can we detect it” to “does detecting it help.” A 2026 review in Frontiers in Immunology frames multi-cancer early detection as a full clinical care pathway rather than a single blood draw, arguing that its value depends on positive and negative predictive values, the false-positive workup that follows a signal, and whether earlier detection actually changes outcomes and cost, not on raw detection rates alone. What this changes for you: a technically impressive test can still fail to help patients if what happens after a positive result isn’t equally well designed.
A separate study published in the Journal of Public Health in March 2026 asked patients, clinicians, and community members directly what they think about these tests, through 23 focus groups involving 158 participants. Most recognized the appeal of a single blood draw, but both patients and doctors said they want stronger evidence before these tests become routine, citing concerns about false positives, overdiagnosis, the time and cost of follow-up care, and unequal access across communities. What this changes for you: the caution built into this month’s panel vote reflects what the people who would actually use this test are already asking for, not just regulatory hesitation.
When to talk to your doctor
This news is a reasonable prompt to bring up cancer screening at your next visit, but the conversation should start with the tests that already have proven benefit for your age and risk profile, not with Galleri. If you are due for a mammogram, a colonoscopy or stool test, a cervical screening, or a lung cancer screening because of smoking history, that is the conversation worth having first. If you are still curious about a multi-cancer blood test after that, ask your doctor about its current limitations, its cost, and what a positive or negative result would actually mean for your specific situation, rather than assuming either outcome settles the question.
Glossary
- Cell-free DNA (cfDNA): small fragments of DNA that circulate freely in the blood, released by both healthy and cancerous cells.
- DNA methylation: a chemical modification to DNA that changes how genes are expressed; cancer cells often show distinctive methylation patterns that tests like Galleri are designed to detect.
- Sensitivity and specificity: sensitivity is a test’s ability to correctly identify people who have a condition; specificity is its ability to correctly identify people who don’t.
- Positive predictive value (PPV): the probability that someone with a positive result actually has the condition being tested for, which depends heavily on how common that condition is in the population being tested.
- Liquid biopsy: any test that looks for signs of cancer in a bodily fluid, most often blood, instead of a tissue sample.
- Premarket approval (PMA): the FDA’s most rigorous review pathway for medical devices, required for a test like Galleri to move from a self-pay laboratory-developed test to an FDA-authorized diagnostic.
This glossary explains only the terms specific to this news update. For general blood test terminology, see the glossary linked in our other articles below.
Frequently asked questions
Did the FDA approve the Galleri test? No. An advisory panel voted that its benefits outweigh its risks, but the FDA itself has not yet issued a final decision, and that decision is expected to take a few months.
What exactly did the panel vote on? Three separate questions: safety (voted 10-0 in favor), effectiveness (voted 6-4 in favor), and whether benefits outweigh risks (voted 7-2 in favor, with one abstention).
How much does the Galleri test cost right now? Reported figures place it at roughly $700 to $900 when paid out of pocket, since it is not currently covered by Medicare or most private insurance.
Does a negative result mean I don’t have cancer? No. Sensitivity is lower for early-stage cancers, which is exactly when a screening test would be most useful, so a negative result cannot rule out cancer.
Should I replace my mammogram or colonoscopy with this test? No. Even its supporters describe it as an addition to established screening, not a substitute for tests with decades of proven benefit.
What happens if the FDA grants final approval? Approval alone would not guarantee insurance coverage. Medicare and private insurers make separate coverage decisions that typically follow, rather than accompany, an FDA approval.
Is there proof this test saves lives? Not yet from a completed randomized controlled trial. The large UK trial designed to answer that question has reported that its primary endpoint on late-stage cancer detection was not met in its first screening round, and further results are still expected.
Sources
- U.S. Food and Drug Administration, meeting announcement for the September 23, 2026 Molecular and Clinical Genetics Panel review of the Galleri test
- National Cancer Institute, Questions and Answers about Multi-Cancer Detection Tests
- KPTV News, coverage of the September 23, 2026 FDA advisory panel vote
- According to research indexed in PubMed: Liquid biopsy, multi-cancer early detection, and artificial intelligence: new frontiers in cancer screening, Frontiers in Immunology, 2026
- According to research indexed in PubMed: Patient, community, and clinician beliefs about multi-cancer detection tests, Journal of Public Health, 2026
Other articles
- Galleri Test FDA Approval: What the September 23 Panel Will Decide
- Multi-cancer early detection test: what the 2026 trial really showed
- Colon cancer blood test coverage
- Lung cancer blood test coverage
Understand your own blood test results with AI DiagMe
Whatever screening path you and your doctor choose, understanding the blood work you already have is a good place to start. AI DiagMe helps you make sense of your own lab results, in plain language, so you can have a more informed conversation at your next appointment. Understand your lab results with AI DiagMe.
